Neuroprotective and reparative effects of carotid body grafts in a chronic MPTP model of Parkinson's disease

Neurobiology of Aging

Volumn 34, Issue 3, 2013, Pages 902-915

  Muñoz Manchado, Ana B ^a,b   Villadiego, Javier ^a,b   Suárez Luna, Nela ^a,b   Bermejo Navas, Alfonso ^a,b   Garrido Gil, Pablo ^b,c   Labandeira García, José L ^b,c   Echevarría, Miriam ^a,b   López Barneo, José ^a,b   Toledo Aral, Juan J ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Carotid body; Cell therapy; Neural transplantation; Neurodegeneration; Neurorestoration; Neurotrophic effect; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID BODY; CELL THERAPY; CONTROLLED STUDY; DENSITOMETRY; DOPAMINERGIC NERVE CELL; GLIA CELL; IMMUNOREACTIVITY; MALE; MOUSE; NERVE REGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPTIC TRACT; OPTICAL DENSITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STEREOLOGY; STEREOTAXIS; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

ANIMALS; CAROTID BODY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MICE; MICE, INBRED C57BL; PARKINSONIAN DISORDERS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84870570183     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.06.001     Document Type: Article

References (71)

1. Alvarez-Fischer D., Guerreiro S., Hunot S., Saurini F., Marien M., Sokoloff P., Hirsch E.C., Hartmann A., Michel P.P. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J. Neurochem 2008, 107:701-711.
2. Arenas E., Trupp M., Akerud P., Ibáñez C.F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 1995, 15:1465-1473.
3. Arjona V., Mínguez-Castellanos A., Montoro R.J., Ortega A., Escamilla F., Toledo-Aral J.J., Pardal R., Méndez-Ferrer S., Martín J.M., Pérez M., Katati M.J., Valencia E., García T., López-Barneo J. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 2003, 53:321-328.
4. Bartus R.T., Brown L., Wilson A., Kruegel B., Siffert J., Johnson E.M., Kordower J.H., Herzog C.D. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol. Dis 2011, 44:38-52.
5. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci 1999, 19:1708-1716.
6. Belzunegui S., Izal-Azcárate A., San Sebastián W., Garrido-Gil P., Vázquez-Claverie M., López B., Marcilla I., Luquin M.R. Striatal carotid body graft promotes differentiation of neural progenitor cells into neurons in the olfactory bulb of adult hemiparkisonian rats. Brain Res 2008, 1217:213-220.
7. Bendotti C., Servadio A., Samanin R. Distribution of GAP-43 mRNA in the brain stem of adult rats as evidenced by in situ hybridization: localization within monoaminergic neurons. J. Neurosci 1991, 11:600-607.
8. Benowitz L.I., Apostolides P.J., Perrone-Bizzozero N., Finklestein S.P., Zwiers H. Anatomical distribution of the growth-associated protein GAP-43/B-50 in the adult rat brain. J. Neurosci 1988, 8:339-352.
9. Björklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., Levivier M., Peschanski M., Studer L., Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003, 2:437-445.
10. Björklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis 1997, 4:186-200.
11. Bjorklund T., Kordower J.H. Gene therapy for Parkinson's disease. Mov. Disord 2010, 25(Suppl 1):S161-S173.
12. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., Tomac A.C., Granholm A.C. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol 2006, 202:336-347.
13. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci 2011, 12:359-366.
14. Dunnett S.B., Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999, 399:A32-A39.
15. Erecińska M., Silver I.A. Tissue oxygen tension and brain sensitivity to hypoxia. Respir. Physiol 2001, 128:263-276.
16. Erickson J.T., Brosenitsch T.A., Katz D.M. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J. Neurosci 2001, 21:581-589.
17. Espejo E.F., Montoro R.J., Armengol J.A., López-Barneo J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 1998, 20:197-206.
18. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
19. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., Lone T., Zhang Y.B., Snyder J.A., Wells T.H., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J. Med 1992, 327:1549-1555.
20. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J. Med 2001, 344. 710-709.
21. Garrido-Gil P., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2012, 9:38.
22. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med 2003, 9:589-595.
23. Goldberg N.R., Haack A.K., Lim N.S., Janson O.K., Meshul C.K. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011, 180:256-271.
24. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc 1987, 147:229-263.
25. Gundersen H.J., Jensen E.B., Kiêu K., Nielsen J. The efficiency of systematic sampling in stereology-reconsidered. J. Microsc 1999, 193:199-211.
26. Hao G., Yao Y., Wang J., Zhang L., Viroonchatapan N., Wang Z.Z. Intrastriatal grafting of glomus cells ameliorates behavioral defects of Parkinsonian rats. Physiol. Behav 2002, 77:519-525.
27. Hidalgo-Figueroa M., Bonilla S., Gutiérrez F., Pascual A., López-Barneo J. GDNF is predominantly expressed in the PV+ neostriatal interneuronal ensemble in normal mouse and after injury of the nigrostriatal pathway. J. Neurosci 2012, 32:864-872.
28. Hoffer B.J., Harvey B.K. Parkinson disease: Is GDNF beneficial in Parkinson disease?. Nat. Rev. Neurol 2011, 7:600-602.
29. Honda Y. Respiratory and circulatory activities in carotid body-resected humans. J. Appl. Physiol 1992, 73:1-8.
30. Izal-Azcárate A., Belzunegui S., San Sebastián W., Garrido-Gil P., Vázquez-Claverie M., López B., Marcilla I., Luquin M.A. Immunohistochemical characterization of the rat carotid body. Respir. Physiol. Neurobiol 2008, 161:95-99.
31. Jacobson R.D., Virág I., Skene J.H. A protein associated with axon growth, GAP-43, is widely distributed and developmentally regulated in rat CNS. J. Neurosci 1986, 6:1843-1855.
32. Kirik D., Georgievska B., Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci 2004, 7:105-110.
33. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Déglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
34. Leitner M.L., Wang L.H., Osborne P.A., Golden J.P., Milbrandt J., Johnson E.M. Expression and function of GDNF family ligands and receptors in the carotid body. Exp. Neurol 2005, 191(Suppl 1):S68-S79.
35. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K.L., Sawle G., Rothwell J.C., Marsden C.D., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247:574-577.
36. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol 2008, 209:82-88.
37. López-Barneo J. Oxygen and glucose sensing by carotid body glomus cells. Curr. Opin. Neurobiol 2003, 13:493-499.
38. López-Barneo J., Pardal R., Ortega-Sáenz P., Durán R., Villadiego J., Toledo-Aral J.J. The neurogenic niche in the carotid body and its applicability to antiparkinsonian cell therapy. J. Neural Transm 2009, 116:975-982.
39. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 2005, 11:703-704.
40. Luquin M.R., Montoro R.J., Guillén J., Saldise L., Insausti R., Del Río J., López-Barneo J. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 1999, 22:743-750.
41. Marin C., Rodriguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol 2006, 197:269-274.
42. McGregor K.H., Gil J., Lahiri S. A morphometric study of the carotid body in chronically hypoxic rats. J. Appl. Physiol 1984, 57:1430-1438.
43. Mejías R., Villadiego J., Pintado C.O., Vime P.J., Gao L., Toledo-Aral J.J., Echevarría M., López-Barneo J. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J. Neurosci 2006, 26:4500-4508.
44. Mínguez-Castellanos A., Escamilla-Sevilla F., Hotton G.R., Toledo-Aral J.J., Ortega-Moreno A., Méndez-Ferrer S., Martín-Linares J.M., Katati M.J., Mir P., Villadiego J., Meersmans M., Pérez-García M., Brooks D.J., Arjona V., López-Barneo J. Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. J. Neurol. Neurosurg. Psychiatry 2007, 78:825-831.
45. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci 1996, 16:436-447.
46. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol 2003, 54:403-414.
47. Pardal R., Ortega-Sáenz P., Durán R., López-Barneo J. Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 2007, 131:364-377.
48. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gómez-Díaz R., López-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci 2008, 11:755-761.
49. Piccini P., Brooks D.J., Björklund A., Gunn R.N., Grasby P.M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H., Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci 1999, 2:1137-1140.
50. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., Quinn N.P., Brooks D.J., Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
51. Piltonen M., Bespalov M.M., Ervasti D., Matilainen T., Sidorova Y.A., Rauvala H., Saarma M., Männistö P.T. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp. Neurol 2009, 219:499-506.
52. Porzionato A., Macchi V., Parenti A., De Caro R. Trophic factors in the carotid body. Int. Rev. Cell Mol. Biol 2008, 269:1-58.
53. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem 2001, 76:1265-1274.
54. Rangasamy S.B., Soderstrom K., Bakay R.A., Kordower J.H. Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res 2010, 184:237-264.
55. Sajadi A., Bensadoun J.C., Schneider B.L., Lo Bianco C., Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol. Dis 2006, 22:119-129.
56. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., Gerhardt G.A., Gash D.M. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol 2006, 202:497-505.
57. Sánchez M.P., Silos-Santiago I., Frisén J., He B., Lira S.A., Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996, 382:70-73.
58. Sauer H., Rosenblad C., Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8935-8939.
59. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res 2001, 125:109-125.
60. Skene J.H., Jacobson R.D., Snipes G.J., McGuire C.B., Norden J.J., Freeman J.A. A protein induced during nerve growth (GAP-43) is a major component of growth-cone membranes. Science 1986, 233:783-786.
61. Thompson L.H., Grealish S., Kirik D., Björklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur. J. Neurosci 2009, 30:625-638.
62. Tillerson J.L., Miller G.W. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods 2003, 123:189-200.
63. Toledo-Aral J.J., Méndez-Ferrer S., Pardal R., Echevarría M., López-Barneo J. Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. J. Neurosci 2003, 23:141-148.
64. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
65. Ugrumov M.V., Khaindrava V.G., Kozina E.A., Kucheryanu V.G., Bocharov E.V., Kryzhanovsky G.N., Kudrin V.S., Narkevich V.B., Klodt P.M., Rayevsky K.S., Pronina T.S. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience 2011, 181:175-188.
66. Villadiego J., Méndez-Ferrer S., Valdés-Sánchez T., Silos-Santiago I., Fariñas I., López-Barneo J., Toledo-Aral J.J. Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation. J. Neurosci 2005, 25:4091-4098.
67. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
68. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., Björklund A., Lindvall O., Langston J.W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J. Med 1992, 327:1556-1563.
69. Yu G., Fournier C., Hess D.C., Borlongan C.V. Transplantation of carotid body cells in the treatment of neurological disorders. Neurosci. Biobehav. Rev 2005, 28:803-810.
70. Yu G., Xu L., Hadman M., Hess D.C., Borlongan C.V. Intracerebral transplantation of carotid body in rats with transient middle cerebral artery occlusion. Brain Res 2004, 1015:50-56.
71. Yurek D.M., Sladek J.R. Dopamine cell replacement: Parkinson's disease. Annu. Rev. Neurosci 1990, 13:415-440.